HDAC6 and triple-negative breast carcinoma: In a study by Lin et al., CRISPR-induced HDAC6 knock-out lines (e.g., melanoma, triple negative breast cancer, colorectal cell lines) demonstrated that the cell viability/proliferation capability was comparable to wildtype controls; additionally, ACY-1215 was able to mediate its anti-cancer effects at high concentrations (micromolar), even when HDAC6 was knocked-out [56].